Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Finasteride Åõ¿© ¶Ç´Â °Å¼¼°¡ ÈòÁã Àü¸³¼±¿¡ ¹ÌÄ¡´Â È¿°ú Effect of Finasteride or Castration on Rat Ventral Prostate

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 8È£ p.717 ~ 722
ÀÓÁ¤È¯, ¿ÀºÀ·Ä, ±è¸í¿ø,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÓÁ¤È¯ (  ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

¿ÀºÀ·Ä (  ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
±è¸í¿ø (  ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
Àü¸³¼±ÀÇ ¹ß»ý°ú ¼ºÀå ±×¸®°í À¯Áö¿¡´Â dihydrotestosterone(DHT)ÀÌ ÇʼöÀûÀε¥ ÀÌ´Â
testosteroneÀÌ 5¥á-reductase¿¡ ÀÇÇØ È¯¿øµÇ¾î Çü¼ºµÇ¸ç, ¼±ÃµÀûÀ¸·Î 5¥á-reductase°¡ °áÇÌ
µÇ¾î ÀÖ´Â ³²ÀÚ´Â Á¤»óÀκ¸´Ù Àü¸³¼±ÀÇ Å©±â°¡ ÀÛ°í, Àü¸³¼±ºñ´ëÁõÀ» ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î
¾Ë·ÁÁ® ÀÖ´Ù. À̸¦ ¹ÙÅÁÀ¸·Î ÃÖ±Ù 5¥á-reductase ¾ïÁ¦Á¦ÀÎ finasteride°¡ °³¹ßµÇ¾î Àü¸³¼±ºñ
´ëÁõ ȯÀÚ¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ´Ù.
ÀÌÀüÀÇ ¸¹Àº ¿¬±¸·ÎºÎÅÍ °Å¼¼ ÈÄ Àü¸³¼±Àº ¼¼Æ÷°í»ç(apoptosls)°úÁ¤À» °ÅÃÄ ¼¼Æ÷»ç¸ÁÀÌ ¹ß
»ýµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÁö¸¸, 5¥á-reductase ¾ïÁ¦Á¦ Åõ¿©½Ã ½Ã°£¿¡ µû¸¥ ¼¼Æ÷»ç¸Á °úÁ¤Àº
Àß ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù µû¶ó¼­5¥á-reductase ¾ïÁ¦Á¦ÀÎ finasterlde´Â ¼¼Æ÷°í»ç ¾øÀÌ ´Ü¼øÇÏ°Ô
Àü¸³¼±ÀÇ ºÐºñ±â´ÉÀ» ¾ïÁ¦ÇϹǷνá Àü¸³¼±ÀÇ ½ÇÁúÀû ¹«°Ô¸¦ °¨¼Ò½ÃÄÑ ÈòÁã Àü¸³¼±À» ÅðÃà
(involution)½ÃŲ´Ù´Â ¼³ÀÌ ÀÖ´Â ¹Ý¸é ¼¼Æ÷°í»ç°¡ Àü¸³¼± ÅðÃàÀÇ ÁÖµÈ ±âÀüÀÌ ¶ó´Â º¸°íµµ
ÀÖ´Ù. ÈòÁãÀÇ º¹Ãø Àü¸³¼±(ventral prostate)Àº 80% Á¤µµ°¡ ³²¼ºÈ£¸£ ÀÇÁ¸¼ºÀÎ Àß ºÐÈ­µÈ ¿ø
ÁÖ»óÇǼ¼Æ÷·Î ±¸¼ºµÇ¾î ÀÖ°í ³²¼º È£¸£¸óÀ» Â÷´Ü½ÃÅ°¸é 2ÁÖ À̳»¿¡ °ÅÀÇ ¸ðµç ¼¼Æ÷°¡ ¼Ò½Ç
µÇ¸ç ¿©±â¿¡ ´Ù½Ã ³²¼º È£¸£¸óÀ» Åõ¿©ÇÏ¸é ¿ÏÀüº¹±¸°¡ µÇ´Â Ư¼ºÀ» °¡Áö°í ÀÖ¾î Àü¸³¼±Àǹß
´Þ, ºÐÈ­ ¹× ¼¼Æ÷»ç¸ÁÀÇ ¿¬±¸¿¡ ¸¹ÀÌ ÀÌ¿ëµÇ°í ÀÖ´Ù.
ÀÌ¿¡ ÀúÀÚµéÀº ÈòÁã¿¡ finasteride¸¦ °æ±¸ Åõ¿©ÇÑ ÈÄ ½Ã°£°æ°ú¿¡ µû¸¥ Àü¸³¼±ÀÇ ¹«°Ô, Àü¸³
¼± Á¶Á÷¿¡¼­ÀÇDHT³óµµ, DNA¾çÀ» ÃøÁ¤ÇÏ°í ¼¼Æ÷°í»ç ¹× »ç¸ÁÀÇ Á¶Á÷ÇÐÀû º¯È­¸¦ °üÂûÇÏ¿©
À̸¦ °Å¼¼ÇÑ ÈòÁãÀÇ ±×°Í°ú ºñ±³ÇÔÀ¸·Î½á finasterideÀÇ Àü¸³¼± ÅðÃàÀÇ Á¤µµ ¹× ±âÀüÀ» Á¶»ç
ÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : We compared the extent of prostatic involution after treatment with
finasteride, a potent 5¥á-reductase inhibitor, with those caused by castration.
Materials and Methods : Rats were divided into two groups: finasteride-treated and
castrated ones. Finasteride-treated rats were given 1mg/kg a day orally. The rats were
sacrificed immediately, and on days 1, 3, 5, 7, 10, 14 and 21 after treatment. The
prostate was immediately removed, weighed and either prepared for histological
examination detecting apoptotic bodies by hematoxylin and rosin staining or frozen in
liquid nitrogen for the determination of intraprostatic DHT concentration and DNA
content, for detection of 180-bp DNA ladder by agarose gel electrophoresis.
Results : Either finasteride or castration decreased prostate weight and DNA content,
which the degree of decrease was more pronounced in castrated group than in
finasteride-treated group. Both finasteride and castration caused a decrease in
intraprostatic DHT concentration, which these processes occurred to a more rapid and
greater extent in finasteride-treated group. By 3 days of finasteride treatment, the
intraprostatic DHT concentration decreased to a greater extent with no further
significant change thereafter, while castration decreased gradually in intraprostatic DHT
concentration up to day 10, with no further significant decrease thereafter. In the pattern
of cell loss determined by hematoxylin and eosin staining, apoptotlc bodies were
observed typically in castration group but not in finasteride-treated group. In agarose
gel electrophoresis, 180-bp DNA ladder was found in finasteride-treated group through
experimental days but in castrated after 3 days of experiment this ladder was not found.
Conclusions : We concluded that castration caused a more profound involution of rat
ventral prostate than finasteride. But the extent of prostatic involution was not
correlated with intraprostatic DHT concentration. Although we could not found the
apoptotic body in finasteride-treated group, the 180-bp DNA ladder suggesting apoptosis
was detected. (Korean J Urol 1998; 39: 717¡­22)

Å°¿öµå

Prostate; Finasteride; Castration; Involution;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS